Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
Logan MooreTrace BartelsDaniel O PerskyIvo AbrahamAbhijeet KumarAli McBridePublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
In this single-center retrospective study, BR-treated lymphoma and CLL patients receiving primary versus secondary with G-CSF showed similar outcomes except, notably, for chemotherapy dose delays that may put secondary patients at risk for poor treatment outcomes. Further research is needed to evaluate the impact of primary versus secondary prophylaxis on treatment outcomes.
Keyphrases
- chronic lymphocytic leukemia
- chemotherapy induced
- diffuse large b cell lymphoma
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- radiation therapy
- adipose tissue
- locally advanced
- patient reported outcomes
- cerebrospinal fluid
- glycemic control
- skeletal muscle